Biocompatibility and buffers: Effect of bicarbonate-buffered peritoneal dialysis fluids on peritoneal cell function

Kidney International

Volumn 54, Issue 6, 1998, Pages 2184-2193

  Jörres, Achim ^a   Bender, Thorsten O ^b   Finn, André ^b   Witowski, Janusz ^b   Fröhlich, Sibylle ^b   Gahl, Gerhard M ^b   Frei, Ulrich ^b   Keck, Heiko ^b   Passlick Deetjen, Jutta ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NONE

Author keywords

Buffers; CAPD; Dialysate; Fibroblasts; Interleukin 6; Mesothelial cells; Peritoneal dialysis

Indexed keywords

BICARBONATE; BUFFER; INTERLEUKIN 1BETA; INTERLEUKIN 6; PERITONEAL DIALYSIS FLUID;

BIOCOMPATIBILITY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME IMMUNOASSAY; HUMAN; HUMAN CELL; MESOTHELIUM CELL; PERITONEAL DIALYSIS; PERITONEUM CELL; PRIORITY JOURNAL;

EID: 0031786152     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1998.00178.x     Document Type: Conference Paper

References (78)

1. DUWE AK, VAS SI, WEATHERHEAD JW: Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis, and bactericidal activity in vitro. Infect Immun 33:130-135, 1981
2. VAN BRONSWIJK H, VERBRUGH HA, HEEZIUS HC, VAN DEN MEULEN J, OE PL, VERHOEF J: Dialysis fluids and local host resistance in patients on continuous ambulatory peritoneal dialysis. Eur J Clin Microbiol Infect Dis 7:368-373, 1988
3. TOPLEY N, ALOBAIDI HM, DAVIES M, COLES GA, WILLIAMS JD, LLOYD D: The effect of dialysate on peritoneal phagocyte oxidative metabolism. Kidney Int 34:404-411, 1988
4. ALOBAIDI HM, COLES GA, DAVIES M, LLOYD D: Host defence in continuous ambulatory peritoneal dialysis: The effect of the dialysate on phagocyte function. Nephrol Dial Transplant 1:16-21, 1986
5. STEINHAUER HB, BRUGGER U, ATMANSPACHER R, LUBRICH-BIRKNER I, SCHOLLMEYER P: Effect of CAPD dialysate on the release of eicosanoids and cytokines from human peritoneal macrophages. Adv Perit Dial 8:47-52, 1992
6. DOUVDEVANI A, ABRAMSON O, TAMIR A, KONFORTY A, ISAKOV N, CHAIMOVITZ C: Commercial dialysate inhibits TNF alpha mRNA expression and NF-kappa B DNA-binding activity in LPS-stimulated macrophages. Kidney Int 47:1537-1545, 1995
7. DOUVDEVANI A, RAPOPORT J, KONFORTY A, YULZARI R, MORAN A, CHAIMOVITZ C: Intracellular acidification mediates the inhibitory effect of peritoneal dialysate on peritoneal macrophages. J Am Soc Nephrol 6:207-213, 1995
8. DOUVDEVANI A, RAPOPORT J, KONFORTI A, ZLOTNIK M, CHAIMOVITZ C: The effect of peritoneal dialysis fluid on the release of IL-1 beta and TNF alpha by macrophages/monocytes. Perit Dial Int 13:112-117, 1993
9. JÖRRES A, TOPLEY N, STEENWEG L, MÜLLER C, KÖTTGEN E, GAHL GM: Inhibition of cytokine synthesis by peritoneal dialysate persists throughout the CAPD cycle. Am J Nephrol 12:80-85, 1992
10. 4 and tumor necrosis factor release from leukocytes: Effect of peritoneal dialysate. Nephron 58:276-282, 1991
11. JÖRRES A, JÖRRES D, TOPLEY N, GAUL GM, MAHIOUT A: Leukotriene release from peripheral and peritoneal leukocytes following exposure to peritoneal dialysis solutions. Nephrol Dial Transplant 6:495-501, 1991
12. GUPTA DK, ING BL, MANAHAN FJ, ZHOU FQ, Yu AW, NAWAB ZM, RAHMAN MA: Superoxide generation by neutrophils after exposure to a conventional peritoneal dialysis solution for different time periods. Int J Artif Organs 13:228-230, 1990
13. ING BL, GUPTA DK, NAWAB ZM, ZHOU FQ, RAHMAN MA, DAUGIRDAS JT: Suppression of neutrophil Superoxide production by conventional peritoneal dialysis solution, Int J Artif Organs 11:351-354, 1988
14. DOBOS GJ, ANDRE M, BÖHLER J, NORGAUER J, LUBRICH-BIRKNER I, STEINHAUER HB, SCHOLLMEYER PJ: Inhibition of C5a-induced actin polymerization, chemotaxis, and phagocytosis of human polymorphonuclear neutrophils incubated in a glucose-based dialysis solution. Adv Perit Dial 9:307-311, 1993
15. YU AW, ZHOU XJ, ZHOU FQ, NAWAB ZM, GANDHI VC, ING TS, VAZIRI ND: Neutrophilic intracellular acidosis induced by conventional, lactate-containing peritoneal dialysis solutions, Int J Artif Organs 15:661-665, 1992
16. LIBEREK T, TOPLEY N, JÖRRES A, PETERSEN MM, COLES GA, GAHL GM, WILLIAMS JD: Peritoneal dialysis fluid inhibition of polymorphonuclear leukocyte respiratory burst activation is related to the lowering of intracellular pH. Nephron 65:260-265, 1993
17. KAUPKE CJ, ZHANG J, RAJPOOT D, WANG J, ZHOU XJ, VAZIRI ND: Effects of conventional peritoneal dialysates on leukocyte adhesion and CD11b, CD18 and CD14 expression. Kidney Int 50:1676-1683, 1996
18. MOORE AL, GRANT BW, DORIGHI JA, BELINSON JL, STEWART JA, ALBERTINI RJ: Effect of commercial peritoneal dialysis fluids on the lytic function of lymphokine-activated killer cells. J Biol Response Mod 7:401-408, 1988
19. VAN BRONSWIJK H, VERBRUGH HA, BOS HJ, HEEZIUS EC, OE PL, VAN DEN MEULEN J, VERHOEF J: Cytotoxic effects of commercial continuous ambulatory peritoneal dialysis (CAPD) fluids and of bacterial exoproducts on human mesothelial cells in vitro. Perit Dial Int 9:197-202, 1989
20. WITOWSKI J, TOPLEY N, JÖRRES A, LIBEREK T, COLES GA, WILLIAMS JD: Effect of lactate-huffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis. Kidney Int 47:282-293, 1995
21. JÖRRES A, GAHL GM, FREI U: Peritoneal dialysis fluid biocompatibility: Does it really matter? Kidney Int 46(Suppl 48):S79-S86, 1994
22. HOLMES CJ: Biocompatibility of peritoneal dialysis solutions. Perit Dial Int 13:88-94, 1993
23. TOPLEY N, COLES GA, WILLIAMS JD: Biocompatibility studies on peritoneal cells. Perit Dial Int 14(Suppl 3):S21-S28, 1994
24. DE FIJTER CW, VERBRUGH HA, PETERS ED, OE PL, VAN DEN MEULEN J, VERHOEF J, DONKER AJ: In vivo exposure to the currently available peritoneal dialysis fluids decreases the function of peritoneal macrophages in CAPD. Clin Nephrol 39:75-80, 1993
25. DE FIJTER CW, VERBRUGH HA, PETERS ED, OE PL, VAN DEN MEULEN J, DONKER AJ, VERHOEF J: Another reason to restrict the use of a hypertonic, glucose-based peritoneal dialysis fluid: Its impact on peritoneal macrophage function in vivo. Adv Perit Dial 7:150-153, 1991
26. GOTLOIB L, SHOSTAK A, WAJSBROT V, KUSCHNIER R: Biocompatibility of dialysis solutions evaluated by histochemical techniques applied to mesothelial cell imprints. Perit Dial Int 13(Suppl 2): S113-S115, 1993
27. GOTLOIB L, WAJSBROT V, SHOSTAK A, KUSHNIER R: Population analysis of mesothelium in situ and in vivo exposed to bicarbonate-buffered peritoneal dialysis fluid. Nephron 73:219-227, 1996
28. GOTLOIB L, WAISBRUT V, SHOSTAK A, KUSHNIER R: Acute and long-term changes observed in imprints of mouse mesothelium exposed to glucose-enriched, lactated, buffered dialysis solutions. Nephron 70:466-477, 1995
29. SCHAMBYE HT, FLESNER P, PEDERSEN RB, HARDT MADSEN M, CHEMNITZ J, CHRISTENSEN HK, DETMER A, PEDERSEN FB: Bicarbonate- versus lactate-based CAPD fluids: A biocompatibility study in rabbits. Perit Dial Int 12:281-286, 1992
30. DI PAOLO N, GAROSI G, PETRINI G, MONACI G: Morphological and morphometric changes in mesothelial cells during peritoneal dialysis in the rabbit. Nephron 74:594-599, 1996
31. FERIANI M, DISSEGNA D, LA GRECA G, PASSLICK DEETJEN J: Shortterm clinical study with bicarbonate-containing peritoneal dialysis solution. Perit Dial Int 13:296-301, 1993
32. FERIANI M: Bicarbonate-buffered CAPD solutions: From clinical trials to clinical practice. Perit Dial Int 17(Suppl 2):S51-S55, 1997
33. FERIANI M, CAROBI C, LA GRECA G, BUONCRISTIANI U, PASSLICK DEETKEN J: Clinical experience with a 39 mmol/L bicarbonate-buffered peritoneal dialysis solution. Perit Dial Int 17:17-21, 1997
34. COLES GA, GOKAL R, OGG C, JANI F, O'DONOGHUE DT, CANCARINU GC, MAIORCA R, TRANAEUS A, FAICT D, DE Vos C: A randomized controlled trial of a bicarbonate- and a bicarbonate/lactate-containing dialysis solution in CAPD. Perit Dial Int 17:48-51, 1997
35. YATZIDIS H, DOMBROS NV, DIGENIS GE: On the usefulness of glycylglycine in hemodialysis and peritoneal dialysis solutions. ASAIO J 42:984-992, 1996
36. TOPLEY N, MACKENZIE RK, PETERSEN MM, BEAVIS MJ, WILLIAMS D, THOMAS N, FAICT D, PELUSO F, COLES GA, DAVIES M, WILLIAMS JD: In vitro testing of a potentially biocompatible continuous ambulatory peritoneal dialysis fluid. Nephrol Dial Transplant 6:574-581, 1991
37. BRUNKHORST R, MAHIOUT A: Pyruvate neutralizes peritoneal dialysate toxicity: Maintained integrity and proliferation of cultured human mesothelial cells. Kidney Int 48:177-181, 1995
38. MAHIOUT A, MATATA BM, BRUNKHORST R: Effect of glucose and pyruvate in acidic and non-acidic peritoneal dialysis fluids on leukocytes cell functions. Kidney Int 51:860-867, 1997
39. MAHIOUT A, BRUNKHORST R: Pyruvate anions neutralize peritoneal dialysate toxicity. Nephrol Dial Transplant 10:391-394, 1995
40. TOPLEY N, BROWN Z, JÖRRES A, WESTWICK J, DAVIES M, COLES GA, WILLIAMS JD: Human peritoneal mesothelial cells synthesize interleukin-8. Synergistic induction by interleukin-1beta and tumor necrosis factor-alpha. Am J Pathol 142:1876-1886, 1993
41. TOPLEY N, JÖRRES A, LUTTMANN W, PETERSEN MM, LANG MJ, THIERAUCH KH, MÜLLER C, COLES GA, DAVIES M, WILLIAMS JD: Human peritoneal mesothelial cells synthesize interleukin-6: Induction by IL-1 beta and TNF alpha. Kidney Int 43:226-233, 1993
42. TOPLEY N, PETERSEN MM, MACKENZIE RK, NEUBAUER A, STYLIANOU E, KAEVER V, DAVIES M, COLES GA, JÖRRES A, WILLIAMS JD: Human peritoneal mesothelial cell prostaglandin synthesis: Induction of cyclooxygenase mRNA by peritoncal macrophage-derived cytokines. Kidney Int 46:900-909, 1994
43. WITOWSKI J, JÖRRES A, COLES GA, WILLIAMS JD, TOPLEY N: Superinduction of IL-6 synthesis in human peritoneal mesothelial cells is related to the induction and stabilization of IL-6 mRNA. Kidney Int 50:1212-1223, 1996
44. BETJES MG, TUK CW, STRUIJK DG, KREDIET RT, ARISZ L, HART M, BEELEN RH: Interleukin-8 production by human peritoneal mesothelial cells in response to tumor necrosis factor-alpha, interleukin-1, and medium conditioned by macrophages cocultured with Staphylococcus epidermidis. J Infect Dis 168:1202-1210, 1993
45. DOUVDEVANI A, RAPOPORT J, KONFORTY A, ARGOV S, OVNAT A, CHAIMOVITZ C: Human peritoneal mesothelial cells synthesize IL-1 alpha and beta. Kidney Int 46:993-1001, 1994
46. DOUVDEVANI A, EINBINDER T, YULZARI R, ROGACHEV B, CHAIMOVITZ C: TNF-receptors on human peritoneal mesothelial cells: Regulation of receptor levels and shedding by IL-1 alpha and TNF alpha. Kidney Int 50:219-228, 1996
47. JÖRRES A, LUDAT K, SANDER K, DUNKEL K, LORENZ F, KECK H, FREI U, GAHL GM: The peritoneal fibroblast and the control of peritoneal inflammation. Kidney Int 50(Suppl 56):S22-S27, 1996
48. JÖRRES A, LUDAT K, LANG J, SANDER K, GAHL GM, FREI U, DEJONGE K, WILLIAMS JD, TOPLEY N: Establishment and functional characterization of human peritoneal fibroblasts in culture: Regulation of interleukin-6 production by proinflammatory cytokines. J Am Soc Nephrol 7:2192-2201, 1996
49. BEAVIS MJ, WILLIAMS JD, HOPPE J, TOPLEY N: Human peritoneal fibroblast proliferation in 3-dimensional culture: Modulation by cytokines, growth factors and peritoneal dialysis effluent. Kidney Int 51:205-215, 1997
50. TOPLEY N, WILLIAMS JD: Role of the peritoneal membrane in the control of inflammation in the peritoneal cavity. Kidney Int 46(Suppl 48):S71-S78, 1994
51. TOPLEY N: The cytokine network controlling peritoneal inflammation. Perit Dial Int 15:S35-S39, 1995
52. TOPLEY N, KAUR D, PETERSEN MM, JÖRRES A, WILLIAMS JD, FAICT D, HOLMES CJ: In vitro effects of bicarbonate and bicarbonate-lactate buffered peritoneal dialysis solutions on mesothelial and neutrophil function. J Am Soc Nephrol 7:218-224, 1996
53. TOPLEY N, KAUR D, PETERSEN MM, JÖRRES A, PASSLICK DEETJEN J, COLES GA, WILLIAMS JD: Biocompatibility of bicarbonate buffered peritoneal dialysis fluids: Influence on mesothelial cell and neutrophil function. Kidney Int 49:1447-1456, 1996
54. STYLIANOU E, JENNER LA, DAVIES M, COLES GA, WILLIAMS JD: Isolation, culture and characterization of human peritoneal mesothelial cells. Kidney Int 37:1563-1570, 1990
55. McGREGOR SJ, TOPLEY N, JÖRRES A, SPEEKENBRINK AB, GORDON A, GAHL GM, JUNOR BJ, BRIGGS JD, BROCK JH: Longitudinal evaluation of peritoneal macrophage function and activation during CAPD: Maturity, cytokine synthesis and arachidonic acid metabolism. Kidney Int 49:525-533, 1996
56. JÖRRES A, GAHL GM, LUDAT K, FREI U, PASSLICK-DEETJEN J: In vitro biocompatibility evaluation of a novel bicarbonate-buffered aminoacid solution for peritoneal dialysis. Nephrol Dial Transplant 12:543-549, 1997
57. JÖRRES A, GAHL GM, TOPLEY N, NEUBAUER A, LUDAT K, MÜLLER C, PASSLICK-DEETJEN J: In vitro-biocompatibility of alternative CAPD fluids; comparison of bicarbonate-buffered and glucose-polymer-based solutions. Nephrol Dial Transplant 9:785-790, 1994
58. PLUM J, SCHOENICKE G, GRABENSEE B: Osmotic agents and buffers in peritoneal dialysis solution: Monocyte cytokine release and in vitro cytotoxicity. Am J Kidney Dis 30:413-422, 1997
59. FISCHER FP, SCHENK U, KIEFER T, HUBEL E, THOMAS S, YATZIDIS H, METTANG T, KUHLMANN U: In vitro effects of bicarbonate-versus lactate-buffered continuous ambulatory peritoneal dialysis fluids on peritoneal macrophage function. Am J Kidney Dis 26:924-933, 1995
60. SCHAMBYE HT, PEDERSEN FB, WANG P: Bicarbonate is not the ultimate answer to the biocompatibility problems of CAPD solutions: A cytotoxicity test of CAPD solutions and effluents. Adv Peril Dial 8:42-46, 1992
61. ING TS, PATEL BP, PATEL JA, PATEL NK, YU AW, OSMAN A, ZHOU FQ: Effects of a pH 7.4, lactate-based and a pH 7.4, bicarbonate-based peritoneal dialysis solutions on neutrophil Superoxide generation, Int J Artif Organs 19:700-703, 1996
62. MANAHAN FJ, ING BL, CHAN JC, GUPTA DK, ZHOU FQ, PAL I, RAHMAN MA: Effects of bicarbonate-containing versus lactate-containing peritoneal dialysis solutions on Superoxide production by human neutrophils. Artif Organs 13:495-497, 1989
63. DOBOS GJ, BURGER M, KUHLMANN J, PASSLICK-DEETJEN J, SCHOLLMEYER P, BÖHLER J: Improved cytosolic free calcium mobilization and superoxide production in bicarbonate-based peritoneal dialysis solution. Nephrol Dial Transplant 12:973-977, 1997
64. SCHAMBYE HT, PEDERSEN FB, CHRISTENSEN HK, BERTHELSEN H, WANG P: The cytotoxicity of continuous ambulatory peritoneal dialysis solutions with different bicarbonate/lactate ratios. Perit Dial Int 13(Suppl 2):S116-S118, 1993
65. SUNDARAM S, CENDOROGLO M, COOKER LA, JABER BL, FAICT D, HOLMES CJ, PEREIRA BJ: Effect of two-chambered bicarbonate lactate-buffered peritoneal dialysis fluids on peripheral blood mononuclear cell and polymorphonuclear cell function in vitro. Am J Kidney Dis 30:680-689, 1997
66. DOBOS GJ, BÖHLER J, KUHLMANN J, ELSNER J, ANDRE M, PASSLICK-DEETJEN J, SCHOLLMEYER PJ: Bicarbonate-based dialysis solution preserves granulocyte functions. Perit Dial Int 14:366-370, 1994
67. FOUGERAY S, SLINGENEYER A, BASTIDE JM, MION C, BASTIDE M: Dialysis solutions buffered with lactate or bicarbonate: In vitro comparison of two dialysis solutions on human peritoneal cell growth from ESRD and non-ESRD patients. Adv Perit Dial 10:235-240, 1994
68. KRISTENSEN SR, PEDERSEN FB: Cytotoxicity testing of two CAPD dialysis fluids in a model system of quiescent fibroblasts. Nephrol Dial Transplant 8:163-167, 1993
69. BUONCRISTIANI U, GALLI F, ROVIDATI S, ALBERTINI MC, COVARELLI C, CAROBI C, DI PAOLO N, CANESTRARI F: Bicarbonate versus lactate buffer in peritoneal dialysis solutions: The beneficial effect on RBC metabolism. Perit Dial Int 16:511-518, 1996
70. ROGACHEV B, HAUSMANN MJ, YULZARI R, WEILER M, HOLMES C, FAICT D, CHAIMOVITZ C, DOUVDEVANI A: Effect of bicarbonate-based dialysis solutions on intracellular pH (pHi) and TNFα production by peritoneal marophages. Perit Dial Int 17:546-553, 1997
71. MACKENZIE RK, HOLMES CJ, MOSELEY A, JENKINS J, WILLIAMS JD, COLES GA, FAICT D, TOPLEY N: Bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage (PMφ) TNFα secretion. J Am Soc Nephrol 9:1499-1506, 1998
72. WIESLANDER AP, NORDIN MK, KJELLSTRAND PT, BOBERG UC: Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929. Kidney Int 40:77-79, 1991
73. MARTINSON E, WIESLANDER AP, KJELLSTRAND PT, BOBERG U: Toxicity of heat sterilized peritoneal dialysis fluids is derived from degradation of glucose. ASAIO J 38:M370-M372, 1992
74. WIESLANDER A, LINDEN T: Glucose degradation and cytotoxicity in PD fluids. Perit Dial Int 16(Suppl 1):S114-S118, 1996
75. WIESLANDER AP, KJELLSTRAND PT, RIPPE B: Heat sterilization of glucose-containing fluids for peritoneal dialysis: Biological consequences of chemical alterations. Perit Dial Int 15:S52-S59, 1995
76. COOKER LA, LUNEBURG P, FAICT D, CHOO C, HOLMES CJ: Reduced glucose degradation products in bicarbonate/lactate-buffered peritoneal dialysis solutions produced in two-chambered bags. Perit Dial Int 17:373-378, 1997
77. WIESLANDER AP, DEPPISCH R, SVENSSON E, FORSBACK G, SPEIDEL R, RIPPE B: In vitro biocompatibility of a heat-sterilized, low-toxic, and less acidic fluid for peritoneal dialysis. Perit Dial Int 15:158-164, 1995
78. WIESLANDER A, FORSBACK G, SVENSSON E, LINDEN T: Cytotoxicity, pH, and glucose degradation products in four different brands of PD fluid. Adv Perit Dial 12:57-60, 1996